Effects of electroporation on cytotoxicity of 4-aminopyrimidin-2- (1H)-one based ligand and its Cobalt (II) and Ruthenium (II) complexes in MCF-7 cancer cells

• Main Author: Mehmet Esref Alkis
• Format: Article
• Language: English
• Published: Dicle University Medical School 2021-09-01
• Series: Dicle Medical Journal
• Subjects: breast cancer; cobalt; ruthenium; cytotoxicity; electroporation
• Online Access: http://diclemedj.org/upload/sayi/82/Dicle%20Med%20J-04604.pdf

Objective: The aim of this study was to investigate the underlying causes of obstetrical disseminated intravascular coagulation (DIC) Objective: Cancer is a complicated disease and ranks near the top among the causes of death across the world. Electrochemotherapy (ECT) is a local treatment method in which chemotherapy and electroporation (EP) are used in combination to facilitate the entry of drugs into cells. The purpose of the study is to examine the cytotoxicity of the cytosine-based ligand and its cobalt and ruthenium complexes in MCF-7 cancer cells and L-929 healthy cells, and to determine the effects of EP on the anticancer activities of these compounds. Methods: In the present study, firstly, the cytotoxic activities of the ligand and its cobalt (Co) and ruthenium (Ru) complexes were examined against MCF-7 cancer cells and L-929 healthy cells. Then, the effects of EP on the anticancer activities of these compounds were examined in MCF-7 cancer cells. Cytotoxicity activities of the compounds were determined by MTT viability test. Results: Co(II) and Ru(II) compounds showed the best cytotoxicity against MCF-7 cancer cells, while they displayed low cytotoxicity against the L-929 healthy cells. EP increased the cytotoxicity of the compounds significantly (p<0.05). A statistically significant decrease was observed in the percentages of cell viability of ligand+EP, Co(II)+EP, and Ru(II)+EP treatment groups compared to those of the compounds-alone and control groups (p <0.05). Conclusion: The results of the present study demonstrated that Co(II) and Ru(II) complexes may contribute as potential chemotherapeutic agents for the treatment of breast cancer and ECT can reduce the side effects of agents by providing treatment with a lower doses of compounds.